Alzheimer's disease treated with combined therapy based on nourishing marrow and reinforcing Qi

Chen Songlin, Yao Xiaoli, Liang Yinying, Mei Weiyi, Liu Xiaoyun, Zhang Changran

Chen Songlin, Yao Xiaoli, Liang Yinying, Department of Neurology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
Mei Weiyi, Department of Cardiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
Liu Xiaoyun, Department of Traditional Chinese Medicine, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
Zhang Changran, Department of Pneumology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China

Supported by the Fund of Science and Technology Project of Guangdong Province (the Mechanism Study for the Therapy of Jianpiyishenfang in Treating Glucocorticoid Tolerance Myasthenia Gravis, No. 2011B090400118)

Correspondence to: Prof. Chen Songlin, Department of Neurology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. csl0711@163.com
Telephone: +86-15913164358, +86-20-82379502
Accepted: August 1, 2014

Abstract

OBJECTIVE: To study the efficacy and safety of combined Traditional Chinese Medicine (TCM) therapy based on nourishing marrow to improve intellect and reinforcing Qi to activate bloodon mild to moderate Alzheimer's disease (AD).

METHODS: Sixty-six patients with AD, whose Mini-Mental State Examination (MMSE) score were from 10-24, were randomized equally into an intervention group and a control group. The control group was given Aricept (5 mg, once daily). The intervention group was further divided into Yang-Qi deficiency (n = 18) and of Yin-Qi deficiency (n = 15) subgroups. Patients in the Yang-Qi deficiency group were intravenously administered Shenfu injection, 60 mL, and deproteinized calf blood injection (DCBI), 1.2 g, once daily. The Yin-Qi deficiency group was given Shenmai injection, 60 mL, and DCBI, 1.2 g, once daily. Each course lasted 21 days.

RESULTS: Compared with the control group and with pre-treatment in the same group, MMSE, clinical dementia rating, and activities of daily living scale scores in the intervention group were significantly improved (all P < 0.05). These metrics mildly improved in the control group compared with before treatment (P > 0.05). No adverse effects were observed in any group during treatment.

CONCLUSION: We found that combined TCM therapy is effective and safe for managing mild to moderate AD.

Key words: Alzheimer disease; Combined modality therapy; Donepezil; Deproteinized calf blood injection

INTRODUCTION

Alzheimer’s disease (AD) is a progressive degenerative disease of the nervous system, which manifests as declined cognitive function, mental behavior, and ability to complete the activities of daily life. The prevalence of AD is increasing as the population ages, placing a heavy burden on families and society. Aricept is effective in the treatment of AD by inhibiting the degradation of acetylcholine in the brain, which increases the concentration of acetylcholine in the cerebral cortex. We aimed to use a combined Traditional Chinese Medicine (TCM) treatment, based on nourishing marrow to improve intellect and reinforcing Qi to activate
blood, to treat mild to moderate AD. We compared this TCM treatment with that of conventional Aricept.

**MATERIALS AND METHODS**

**Diagnosis criteria**
AD was diagnosed according to the American Diagnostic and Statistical Manual of Mental Disorders and the standard diagnosis criteria of the National Institute of Neurological Disorders and Stroke.3

**Inclusion and exclusion criteria**
Patients were included if they: (a) met the diagnostic criteria; (b) were ≥55 years old; (c) had a MMSE score from 10-24; (d) were able to see, hear, speak to accomplish each measurement; (e) agreed to the treatment and signed their informed consent. This treatment was approved by the Medical Ethics Committee of First Affiliated Hospital of Zhongshan University.

The exclusion criteria included: (a) dementia caused by other disease, such as vascular disease, brain trauma, encephalitis, Parkinson’s disease and other problems; (b) patients who received prior treatment for AD; (c) patients who had other severe cardiovascular, hepatic, or renal disease.

**Patient grouping**
Sixty-six AD patients were treated in the Department of Neurology or Traditional Chinese medicine (TCM) of the First Affiliated Hospital of Sun Yat-sun University, from 2007 to 2013. Patients were randomized equally into an intervention group and control group using the software SPSS 12.0 (SPSS, Chicago, IL, USA). The intervention group was further divided into the Yang-Qi deficiency (n = 18) and Yin-Qi deficiency subgroups (n = 15), as previously described.1 Study subjects were blinded to treatments, while result evaluators were unblinded.

There were no significant differences among groups in terms of age, gender, disease course, pathogenic conditions, including the mini-mental state examination (MMSE) scores, clinical dementia rating (CDR) scores, activities of daily living scale (ADL) scores, or years of education before treatment (all P > 0.05) (Table 1).

**Treatment**
Patients in the control group were orally administered 5 mg of Aricept (Eisai pharmaceutical [Suzhou] Co., Ltd., batch No. H20050978, Suzhou, China) once a night. Patients in the Yang-Qi deficiency subgroup were intravenously administered Shenfu injection (Ya’an 999 Pharmaceutical Co., Ltd., Ya’an, China; batch No. Z51020664), which is composed of Hongshen (Radix Ginseng Rubra) and Fuzi (Radix Aconiti Lateralis Preparata), 60 mL via intravenous drip, once a day. The Yang-Qi deficiency subgroup was also given deproteinized calf blood injection, (DCBII, Jinzhou Aohong Pharmaceutical Co., Ltd., Jinzhou, China; batch No. H20010762; one 10 mL ampoule contains 0.4 g) 1.2 g, intravenous drip, once daily. The Yin-Qi deficiency subgroup was intravenously administered 60 mL of Shenmai injection (Ya’an 999 Pharmaceutical Co., Ltd., batch No. Z51021879), which is composed of Hongshen (Radix Ginseng Rubra) and Maidong (Radix Ophiopogonis Japonici) once daily, plus 1.2 g of DCBII once daily via intravenous drip. The treatment course for both groups was 21 days.

**RESULTS**

**Cognitive function**
From before to after treatment, MMSE scores increased from 16.8 ± 4.3 to 27.7 ± 2.0 in the intervention group (P < 0.05), and 15.2 ± 4.7 to 17.7 ± 2.4 in the control group (P > 0.05). The MMSE score increased more significantly in the intervention group than that in the control group (P < 0.05) (Table 2).

**Dementia level score**
After treatment, the CDR scores decreased significantly in the intervention group (P < 0.05), while the control group scores decreased mildly compared to before treatment (P > 0.05). The decrease in the CDR score was significantly greater in the intervention group than that in the control group (P < 0.05) (Table 2).

**Self-care ability in daily living**
After treatment, the ADL scores significantly decreased in the intervention group (P < 0.05), while the control group scores were decreased mildly compared with before treatment (P > 0.05). The decrease in the ADL score was significantly greater in the intervention group than that in the control group (P < 0.05) (Table 2).
It's effect. We found that Aricept did not improve the cognitive dysfunction. While acetylcholinesterase inhibitors inhibit acetylcholine degradation in the central system has been shown to improve cognition, and therefore reduced acetylcholine concentration in the neurons of the cerebral cortex. AD symptoms resulted from decreased choline acetyltransferase activity and therefore reduced acetylcholine concentration in the brain. Aricept is a specific inhibitor of acetylcholinesterase, and inhibition of acetylcholine degradation in the central system has been shown to improve cognitive dysfunction. While acetylcholinesterase inhibitors can improve cognitive function in patients with AD after 4 weeks, it must be taken continuously to maintain its effect. We found that Aricept did not improve the manifestation of AD after 21 days, which is consistent with other reports. However, the combined TCM intervention group had significantly improved MMSE, CDR, and ADL scores compared with before treatment and compared with the control group (all P < 0.05).

DISCUSSION

AD is a neurodegenerative disorder of the central nervous system. The clinical manifestation of AD is thought to be caused by acetylcholine dysfunction in the neurons of the cerebral cortex. AD symptoms result from decreased choline acetyltransferase activity and therefore reduced acetylcholine concentration in the brain. Aricept is a specific inhibitor of acetylcholinesterase, and inhibition of acetylcholine degradation in the central system has been shown to improve cognitive dysfunction. While acetylcholinesterase inhibitors can improve cognitive function in patients with AD after 4 weeks, it must be taken continuously to maintain its effect. We found that Aricept did not improve the

In the intervention group, drugs were withdrawn after 3 weeks of treatment, and there was no noticeable symptom rebounding after 12 weeks of follow-up. The control group maintained administration of Aricept.

Adverse reactions

No abnormal changes were found in the laboratory examination in either group. No abnormal changes were found in the neurologic examination, vital signs, electrocardiogram, or chest X-ray in either group. During treatment, four patients in the intervention group experienced mild dizziness, but symptoms improved after slowing down the speed of medicine infusion. In the control group, three patients suffered from excitation and insomnia, but changing the time of Aricept administration from night to morning improved the symptoms. No adverse reactions that impacted treatment were observed.

| Table 1 Alzheimer’s patient information in both treatment groups ( x ± s ) |
|---|---|---|---|---|---|---|---|
| Group | n | Male (n) | Female (n) | MMSE | CDR | ADLS | Age (years) | Course of disease (years) |
| Intervention | 33 | 20 | 13 | 16.8±4.3 | 1.5±0.4 | 46.2±7.9 | 9.1±5.3 | 67.9±13.3 | 3.9±2.9 |
| Control | 33 | 18 | 15 | 15.2±4.7 | 1.6±0.5 | 47.3±6.1 | 8.3±4.7 | 69.2±15.7 | 3.7±3.1 |

Notes: the control group was orally administered Aricept. The intervention group was further divided into the Yang-Qi deficiency (n = 18) and Yin-Qi deficiency subgroups (n = 15). Patients in the Yang-Qi deficiency subgroup were intravenously administered Shenfu injection plus a deproteinized calf blood injection. The Yin-Qi deficiency subgroup was intravenously administered Shenmai injection plus a deproteinized calf blood injection. MMSE: mini-mental state examination; CDR: clinical dementia rating; ADLS: activities of daily living scale.

| Table 2 Changes in rating scales of Alzheimer’s patients before and after treatment ( x ± s ) |
|---|---|---|---|---|---|---|---|
| Group | n | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
| Intervention | 33 | 16.8±4.3 | 27.7±2.0<sup>a</sup> | 1.5±0.4 | 0.8±0.3<sup>a</sup> | 46.2±7.9 | 29.5±7.6<sup>a</sup> |
| Control | 33 | 15.2±4.7 | 17.7±2.4 | 1.6±0.5 | 1.4±0.4 | 47.3±6.1 | 41.5±6.3 |

Notes: the control group was orally administered Aricept. The intervention group was further divided into the Yang-Qi deficiency (n = 18) and Yin-Qi deficiency subgroups (n = 15). Patients in the Yang-Qi deficiency subgroup were intravenously administered Shenfu injection plus a deproteinized calf blood injection. The Yin-Qi deficiency subgroup was intravenously administered Shenmai injection plus a deproteinized calf blood injection. MMSE: mini-mental state examination; CDR: clinical dementia rating; ADLS: activities of daily living scale. <sup>a</sup>P < 0.05, compared with the pre-treatment in the same group. <sup>b</sup>P < 0.05, compared with the control group after treatment.

According to TCM, the fundamental etiology and pathogenesis of AD is Kidney deficiency. Congestion and muddy phlegm are important factors for the onset of AD. Yi Xue Xin Wu et al. stated that ‘intellect is based on kidney. Kidney deficiency leads to mental retardation,’ and ‘insufficiency of kidney essence leads to brain marrow dystrophy, and dementia.’ AD is considered to lead to stagnant blood and muddy phlegm accumulation because of the deficiency of Qi and blood, and dysfunction of viscera. Ling Shu Ying Wei Sheng Hui et al. stated that ‘Qi and blood of the elderly is deficient. Their muscles are withered and consumed, Qi-pas-sages are stagnant, nutrient Qi is declined, and defense Qi is subjugated inwardly.’ Therefore, AD treatment should include the pathogenic factors of kidney deficiency, marrow vacancy, and blood stagnancy because of Qi deficiency. Moreover, treatment should focus on invigorating the kidney to consolidate semen, nourishing the cerebral marrow to improve intellect, and reinforcing Qi to activate blood.

When treating AD in TCM, reinforcing kidney is emphasized. TCM treatment aims to increase essence and marrow to nourish the brain. DCBI has been shown to significantly improve damaged brain cells, and can provide protection and nutrition, and restore cerebral neurons via multiple targets. These effects from DCBI are similar to nourishing marrow to improve intellect in TCM.
DCBI can activate aerobic metabolism, and increase the production of ATP in the mitochondria, which increases the use of oxygen in neurons. DCBI also contains phosphoinositide oligosaccharides, which can stop nitric oxide (NO) synthesis by inhibiting NO synthase. Therefore, DCBI blocks the NO-mediated ischemic cascade and prevents cell damage.13 We found that DCBI combined with Shenmai or Shenfu was very effective for AD. After 21 days of treatment, the MMSE, CDR, and ADL scores in the intervention group were all improved (all P < 0.05). The combined therapy may repair the neuronal damage that causes AD at the molecular and cellular levels.

Hongshen (Radix Ginseng Rubra) is the main ingredient in the Shenmai and Shenfu injections. The main bioactive compounds found in Hongshen (Radix Ginseng Rubra) are ginseng saponins, which have neuroprotective functions and can enhance brain energy metabolism. They also can reduce NO production, prevent free radical damage, protect neurons, increase synaptic neurotransmitter uptake, and significantly inhibit acetylcholinesterase. Moreover, ginseng saponins can regulate immune function and enhance memory in the central nervous system. Ginsenosides Rb1 and Rg1, which are ginseng saponins, can increase the density of muscarinic acetylcholine receptors. By inhibiting the cAMP-dependent phosphodiesterase in the hippocampus of aged rats, ginseng saponins can also reduce the concentration of intracellular synaptic calcium ions, and resist excitatory amino acid neurotoxicity to protect nerve cells. Therefore, Hongshen (Radix Ginseng Rubra) has possible anti-AD effects.14 In TCM, Hongshen (Radix Ginseng Rubra) nourishes the brain and reinforces intelligence. It can also reinforce Qi to activate and improve blood circulation, which helps other drugs reach the lesions. *Ben Cao Jing Shu*, a classic Chinese treatise for description of the properties and functions of Traditional Chinese Medicine,15 stated that "Hongshen (Radix Ginseng Rubra) can tonify genuine Yang Qi of the five Zang-organs and is effective in patients suffering from genuine Yang exhaustion and kidney Qi deficiency." According to TCM theories, Qi deficiency is divided into Yang-Qi deficiency and Yin-Qi deficiency.16 Patients with Yang-Qi deficiency often have cold limbs, the need to urinate frequently at night, slight desire to talk, shortness of breath, devitalized essence-spirit, a pale and fat tongue with scallomed edges, glossy white or slimy white tongue fur, and a deep, fine, and weak pulse or floating, large, and weak pulse. Patients with Yin-Qi deficiency often have a pale white complexion, pallor, palpitation, reduced sleep, forgetfulness, vexation, a dry mouth, tinnitus, backbone, limb knees, red tongue with scanty fur, and a fine, string-like pulse. Treatment based on syndrome differentiation results in the best treatment effect.

Shenfu injection is prepared from Hongshen (Radix Ginseng Rubra) and Fuzi (Radix Aconiti Lateralis Preparata). Hongshen (Radix Ginseng Rubra) can tonify Qi, prevent exhaustion, and nourish Qi to vitalize the blood. Fuzi (Radix Aconiti Lateralis Preparata) can assist Yang with pungent warmth and free the twelve channels. The combination of the two medicines can boost Qi, warm Yang, move blood, and free channels. Shenfu injection contains ginsenosides, water-soluble alkaloids, and many other biologically active components. The injection can improve brain energy metabolism by increasing cerebral blood flow and slowing down the damage of cellular structures by preventing intracellular calcium overload.17 Fuzi (Radix Aconiti Lateralis Preparata) has glucocorticoid-like anti-inflammatory effects. Compounds found in the herb can dilate brain arteries and improve brain hypoxia via anti-coagulation and anti-platelet aggregation effects. The drug can also restore brain neuron injury.18

Shengmai injection is prepared from Hongshen (Radix Ginseng Rubra) and Maidong (Radix Ophiopogonis Japonici). Maidong (Radix Ophiopogonis Japonici) has a slightly cold nature that nourishes Yin and boosts Qi. Shengmai injection can boost Qi, nourish blood and Yin, and vitalize liquids.19 The pattern type in TCM provides a basis for TCM treatment and does not affect treatment efficacy evaluation. Therefore, we did not distinguish or analyze effectiveness between the TCM pattern types. Our TCM-based protocol aims to manage AD by nourishing marrow to improve intellect and reinforcing Qi to activate blood. DCBI combined with Shenfu or Shenmai has definitive effects on improving the symptoms of mild to moderate AD in terms of cognitive function, dementia, and self-care ability in daily living. During treatment, no adverse effects that affected the treatment were observed.

REFERENCES


